Active immunologic stimulation has the potential of killing the “last” leukemic cell once the total number of tumor cells is reduced to about 105 by chemo- and radiotherapy. A plateau in remission duration has now persisted for more than five years in about a third of patients so treated. Thus far the favorable prognosis is confined to patients in whom the lymphoid proliferation is primarily microlymphoblastic or prolymphocytic.